Japan Exports to U.S. Rebound in November as Tariff Impact Eases, Boosting BOJ Rate Hike Expectations 
Singapore Growth Outlook Brightens for 2025 as Economists Flag AI and Geopolitical Risks 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Oil Prices Climb on Venezuela Blockade, Russia Sanctions Fears, and Supply Risks 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
New Zealand Business Confidence Hits 30-Year High as Economic Outlook Improves 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
BOJ Poised for Historic Rate Hike as Japan Signals Shift Toward Monetary Normalization 
Dollar Holds Firm Ahead of Global Central Bank Decisions as Yen, Sterling and Euro React 
Gold and Silver Surge as Safe Haven Demand Rises on U.S. Economic Uncertainty 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Asian Markets Rebound as Tech Rally Lifts Wall Street, Investors Brace for BOJ Rate Hike 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Samsung C&T attributed its first-quarter net profit surge of 55.8 percent to equity gains from its affiliate Samsung Biologics and profitable overseas projects.
The company, a construction affiliate of the Samsung Group, said in a regulatory filing that it had a net profit of 346.5 billion won for January to March, up from 222.4 billion won in the same period a year before.
Samsung C&T owns a 43.3 percent share in Samsung Biologics, a biopharmaceutical unit of Samsung Group.
The company claimed a first-quarter increase of 39.8 percent in its operating profit to 147 billion from 105 billion won in the same period last year.
However, Samsung C&T's revenue of 6.96 trillion won is a 5.4 percent dip from 7.35 trillion won last year. It attributed the drop to decreasing domestic consumption, and trading volume brought about by the COVID-19 situation, and for the completion of construction projects undertaken by the company.
Shares in Samsung C&T is up 3.3 percent to 97,000 won, outperforming KOSPI's gain of 0.89 percent gain.
"Increased equity gains from Samsung Biologics and profitable overseas projects boosted the first-quarter net profit," an official of Samsung C&T said.
